Hector Bolivar is an Infectious Disease physician affiliated with University of Miami. OpenAlex indexes 44 publications with 916 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1611 NW 12th Ave
Box 016960 M851
Miami, FL 331361005
Telephone
305-243-4664Registry record last updated 30 Aug 2013.
Clinical trials
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Sponsor: CAN Community Health
- Phage Therapy for the Prevention and Treatment of Pressure Ulcers.
Sponsor: Precisio Biotix Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year202541 payments$12,885openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202524 payments
- Paratek Pharmaceuticals, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
79.2%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor43.5%Dovato64%Tivicay19%Juluca16%Part D<11 patientsProtease Inhibitor12.5%Prezcobix100%Part D<11 patients+ 3 more classes in this area
Cardiovascular
20.8%Statin12.5%Atorvastatin Calcium100%Part D<11 patientsBeta blocker8.3%Metoprolol Succinate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size
JAIDS Journal of Acquired Immune Deficiency Syndromes
2024 - Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV
AIDS Research and Human Retroviruses
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Sebastian Koch, MD
University of Miami
Jay Spiegel, MD
University of Miami
Kara Cavuoto, MD
University of Miami
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”